

Document Template

Comprehensive EHR documentation of patient medical histories can help support efforts to avoid failed prior authorization (PA) requests. Once a prescriber has determined the appropriate patient for PRALUENT, EHR medical history reports can help support a prior authorization request. Knowledge of payer utilization management criteria and patient medical history reports can help to reduce submission of patients who are not PA criteria eligible.

Greenway Intergy supports the ability to print a Document Template, which may assist in the completion of payer PA forms. Available clinical data that can be listed on the Document Template include diagnosis, current and prior medications, lab values, and other clinical or patient demographic information. For PRALUENT, PA criteria may require a diagnosis of established cardiovascular disease (eg, myocardial infarction, stroke or unstable angina requiring hospitalization) with or without concomitant use of maximally tolerated statin therapy (eg, atorvastatin 40 mg/day), and LDL-C ≥ 70 mg/dL or ≥ 100 mg/dL, depending on insurance.

INDICATIONS AND USAGE

PRALUENT (alirocumab) is indicated:

- to reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease
- as an adjunct to diet, alone or in combination with other lipid-lowering therapies (e.g., statins, ezetimibe), for the treatment of adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia) to reduce low-density lipoprotein cholesterol (LDL-C)

IMPORTANT SAFETY INFORMATION

- PRALUENT is contraindicated in patients with a history of a serious hypersensitivity reaction to PRALUENT, including hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization


Please see accompanying full [Prescribing Information](#)



To Create a Document Template:


After a patient has been identified by a prescriber as appropriate for treatment with PRALUENT, a Document Template may be printed to support PA requirements. The following steps illustrate how to create a Document Template containing clinical and patient demographic information necessary to complete a prior authorization form.

1. Navigate to **Intergy EHR blue button > Setup > Document Templates**
2. Select **New**



The screenshot shows the "Document Template Setup" dialog box. At the top right, there are buttons for help (?) and close (X). Below the title bar, there is a "Template for:" dropdown menu set to "Shared". To the right of this are two checkboxes: "Show Inactive Templates" and "Show Detail", both of which are unchecked. The main area of the dialog contains a list of categories with expand/collapse icons: "Provider", "Patient", "Facility", and "Encounter Note". At the bottom, there is a row of buttons: "New", "Edit", "Delete", "Copy", "Deactivate", "Mark as Favorite", and "Close".

3. Define the New Template and select **Save**



The screenshot shows the "New Template" dialog box. At the top right, there are buttons for help (?) and close (X). Below the title bar, there is a "Type:" section with a radio button selected for "Shared" and a "Personal for Provider:" dropdown menu. Below this is a "Description:" text field containing "Prior Authorization" and a "Class:" dropdown menu set to "Patient". There are three radio button options: "Use wizard to create template", "Start with existing template:" (with a "Select Template" dropdown), and "Use blank template" (which is selected). At the bottom, there is a "Make as Favorite" checkbox and "Save" and "Cancel" buttons.

IMPORTANT SAFETY INFORMATION

- Hypersensitivity reactions (e.g., pruritus, rash, urticaria), including some serious events (e.g., hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization), have been reported with PRALUENT treatment. If signs or symptoms of serious allergic reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve


Please see accompanying full [Prescribing Information](#)



Praluent[®]
(alirocumab) Injection 75mg/mL
150mg/mL
Redefining Possible

Prior Authorization Information

Greenway Intergy



4. Select **Insert** and choose criteria for the Document Template, for example patient **Demographic** information and **Encounter** information such as diagnoses, medication history, procedure history and lab values.

Please see accompanying full [Prescribing Information](#)


Praluent[®]
(alirocumab) Injection 75mg/mL
150mg/mL
Redefining Possible

To Create Document Template Printout:

Important Note: For data to appear correctly in the Document Template Printout, criteria such as Prior Medications, Labs Results, Problem Lists, and Past Medical History must be cited or documented within an Encounter Note. The Encounter Note must be OPEN for the templated information to print correctly.

1. Navigate to **IEHR Blue Button** and Select **Patient**
2. Select **Generate Correspondence**
3. Select **Patient** radio button and the appropriate **Document Template**
4. Choose **Print Now**

Clinical Correspondence [?] [X]

Test, Patient [Untitled - Edited]

Letter From:
Patient Encounter: [] Note is Unsigned

Send to: Provider Facility Patient Insurance Employer

To Patient: **To Patient:** via

Letter Template:

Print Now Archive Only Save and Finish Later Assign to User

Notes for Task: []

Preview OK Cancel

INDICATIONS AND USAGE

PRALUENT (alirocumab) is indicated:

- to reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease
- as an adjunct to diet, alone or in combination with other lipid-lowering therapies (e.g., statins, ezetimibe), for the treatment of adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia) to reduce low-density lipoprotein cholesterol (LDL-C)

IMPORTANT SAFETY INFORMATION

- PRALUENT is contraindicated in patients with a history of a serious hypersensitivity reaction to PRALUENT, including hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization
- Hypersensitivity reactions (e.g., pruritus, rash, urticaria), including some serious events (e.g., hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization), have been reported with PRALUENT treatment. If signs or symptoms of serious allergic reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve
- The most commonly occurring adverse reactions in clinical trials in primary hyperlipidemia (including heterozygous familial hypercholesterolemia (HeFH)) ($\geq 5\%$ of patients treated with PRALUENT and occurring more frequently than with placebo) are nasopharyngitis, injection site reactions, and influenza
- The most commonly occurring adverse reactions in the cardiovascular outcomes trial ($>5\%$ of patients treated with PRALUENT and occurring more frequently than placebo) were non-cardiac chest pain, nasopharyngitis, and myalgia
- In the primary hyperlipidemia (including HeFH) clinical trials, local injection site reactions including erythema/redness, itching, swelling, and pain/tenderness were reported more frequently in patients treated with PRALUENT 75 mg and/or 150 mg every 2 weeks (7.2% versus 5.1% for PRALUENT and placebo, respectively). Few patients discontinued treatment because of these reactions (0.2% versus 0.4% for PRALUENT and placebo, respectively), but patients receiving PRALUENT had a greater number of injection site reactions, had more reports of associated symptoms, and had reactions of longer average duration than patients receiving placebo
- The once-monthly (Q4W) 300mg dosing regimen had a higher rate of local injection site reactions as compared to PRALUENT 75mg Q2W or placebo (16.6%, 9.6%, and 7.9%, respectively) in a trial in which all patients received an injection of drug or placebo every 2 weeks to maintain the blind. The discontinuation rate due to injection site reactions was 0.7% in the 300 mg Q4W arm and 0% in the other 2 arms

Please see accompanying full [Prescribing Information](#)



Praluent[®]
(alirocumab) Injection 75mg/mL
150mg/mL
Redefining Possible

IMPORTANT SAFETY INFORMATION (*cont.*)

- In a cardiovascular outcomes trial, local injection site reactions were reported in 3.8% of patients treated with PRALUENT versus 2.1% patients treated with placebo, and led to permanent discontinuation in 0.3% of patients versus <0.1% of patients, respectively
- In the primary hyperlipidemia trials, liver-related disorders (primarily related to abnormalities in liver enzymes) were reported in 2.5% of patients treated with PRALUENT and 1.8% of patients treated with placebo, leading to treatment discontinuation in 0.4% and 0.2% of patients, respectively. Increases in serum transaminases to greater than 3 times the upper limit of normal occurred in 1.7% of patients treated with PRALUENT and 1.4% of patients treated with placebo
- In the primary hyperlipidemia trials, the most common adverse reactions leading to treatment discontinuation in patients treated with PRALUENT were allergic reactions (0.6% versus 0.2% for PRALUENT and placebo, respectively) and elevated liver enzymes (0.3% versus <0.1%)
- PRALUENT is a human monoclonal antibody. As with all therapeutic proteins, there is a potential for immunogenicity with PRALUENT

Please see accompanying full [Prescribing Information](#)



©2019 Sanofi and Regeneron Pharmaceuticals, Inc.
All rights reserved. 07/19 SAUS.PRL.1712.9327(1)

